Weighted Average Number of Shares Outstanding, Basic of Lyell Immunopharma, Inc. from 2019 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Lyell Immunopharma, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from 2019 to Q3 2025.
  • Lyell Immunopharma, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2025 was 18.3M shares, a 42.6% increase year-over-year.
  • Lyell Immunopharma, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 261M shares, a 4.18% increase from 2023.
  • Lyell Immunopharma, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 251M shares, a 1.58% increase from 2022.
  • Lyell Immunopharma, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 247M shares, a 81.8% increase from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Growth (%)

Lyell Immunopharma, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 18.3M +5.45M +42.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 14.8M +2.02M +15.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 295M +40.8M +16.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 261M +10.5M +4.18% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-11
Q3 2024 12.8M -239M -94.9% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 12.8M -237M -94.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 254M +4.66M +1.87% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 251M +3.9M +1.58% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-11
Q3 2023 251M +3M +1.21% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 250M +3.89M +1.58% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 250M +5.41M +2.22% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 247M +111M +81.8% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-11
Q3 2022 248M +8.94M +3.73% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 246M +204M +477% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 244M +227M +1314% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 136M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 239M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 42.7M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 17.3M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10

Lyell Immunopharma, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 261M +10.5M +4.18% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-11
2023 251M +3.9M +1.58% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-11
2022 247M +111M +81.8% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-11
2021 136M +123M +925% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 13.3M +13.3M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 5.43K* Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.